Author

A. Pellagatti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Verma· 2 shared J. Boultwood· 2 shared K. Pradhan· 2 shared U. Steidl· 2 shared A. Shastri· 1 shared A. Wickrema· 1 shared B. Agianian· 1 shared B. Aylward· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Verma

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolism.

B. Harris, D. K. Singh, B. Truong, M. Rhodes, R. Price, S. Shinton, M. Verma, B. Aylward, S. P. Fahl, S. R. Sprinkle, S. Aminov, M. Wang, Y. Zhang, J. Perrigoue, R. Kessel, , D. L. Wiest

This study shows that reduced RPL22 expression in hematopoietic stem cells promotes leukemia by altering metabolism and increasing lipid synthesis via Lin28b.

bioRxiv · May 31, 2023Cancer Biology

Activation of targetable inflammatory immune signaling is seen in Myelodysplastic Syndromes with SF3B1 mutations

G. Choudhary, A. Pellagatti, B. Agianian, M. Smith, T. D. Bhagat, S. Gordon-Mitchell, S. Pandey, N. Shah, S. Aluri, L. Schwartz, V. Steeples, R. Booher, M. Ramachandra, M. Samson, M. Carbajal, , A. Verma

This study identifies a longer, oncogenic IRAK4 isoform caused by SF3B1 mutations in MDS/AML, which is targetable by IRAK4 inhibition.

bioRxiv · Mar 9, 2022Cancer Biology